Skip to main content
Premium Trial:

Request an Annual Quote

Sponsored
By Biognosys

Next-Generation Proteomics Delivers Insights Across the Oncology Pipeline: Highlights from the AACR 2022 Annual Meeting

Advances in proteomics are improving cancer biomarker discovery, drug discovery, and drug target validation.

By Biognosys

Mass Spectrometry is Fueling Advancements in Plasma Proteomics for Biomarker Discovery

Plasma and serum are brimming with potential protein biomarkers that can provide detailed information about health and disease mechanisms without the need for invasive medical procedures.

By F. Hoffmann-La Roche Ltd.

New TMB Recommendations Help to Guide Treatment Decisions in Oncology

Recent recommendations from the ESMO Precision Medicine Working Group and National Comprehensive Cancer Network, coupled with US Food and Drug Administration review and approval, have highlighted the use of tumor mutational burden testing in clinical practice for a number of different tumor types. 

By Biognosys

Going Beyond Genomics with Next-Generation Proteomics to Accelerate Precision Oncology

In recent years, the field of proteomics has undergone a transformation, enabling quantitative analysis of more than 10,000 proteins across thousands of samples, while advances in structural chemoproteomics allow researchers to map drug binding sites with unprecedented resolution. These next-generation proteomics approaches are driving significant progress in precision oncology. 

By F. Hoffmann-La Roche Ltd.

Putting Personalized Healthcare at the Heart of Clinical Practice

The COVID-19 pandemic has caused massive disruption to cancer care. Delays in diagnosis and treatment highlight the importance of establishing a personalized healthcare approach that provides tailored care, integrates innovation, and supports equal access to cancer care.